197 related articles for article (PubMed ID: 22329832)
21. Coordinate expression of Cdc25B and ER-alpha is frequent in low-grade endometrioid endometrial carcinoma but uncommon in high-grade endometrioid and nonendometrioid carcinomas.
Wu W; Slomovitz BM; Celestino J; Chung L; Thornton A; Lu KH
Cancer Res; 2003 Oct; 63(19):6195-9. PubMed ID: 14559803
[TBL] [Abstract][Full Text] [Related]
22. Estrogen receptor expression and increased risk of lymphovascular space invasion in high-grade serous ovarian carcinoma.
Matsuo K; Sheridan TB; Mabuchi S; Yoshino K; Hasegawa K; Studeman KD; Im DD; Rosenshein NB; Roman LD; Sood AK
Gynecol Oncol; 2014 Jun; 133(3):473-9. PubMed ID: 24674832
[TBL] [Abstract][Full Text] [Related]
23. Comparative Survival Outcomes of Uterine Papillary Serous Carcinoma, Clear Cell Carcinoma, Grade 3 Endometrioid Adenocarcinoma, and Carcinosarcoma of Endometrial Cancer in Rajavithi Hospital.
Prueksaritanond N; Chantape W
J Med Assoc Thai; 2016 Feb; 99 Suppl 2():S75-83. PubMed ID: 27266220
[TBL] [Abstract][Full Text] [Related]
24. Selected immunohistochemical prognostic factors in endometrial cancer.
Markova I; Duskova M; Lubusky M; Kudela M; Zapletalová J; Procházka M; Pilka R
Int J Gynecol Cancer; 2010 May; 20(4):576-82. PubMed ID: 20686376
[TBL] [Abstract][Full Text] [Related]
25. An updated clinicopathologic study of early-stage uterine papillary serous carcinoma (UPSC).
Fader AN; Starks D; Gehrig PA; Secord AA; Frasure HE; O'Malley DM; Tuller ER; Rose PG; Havrilesky LJ; Moore KN; Huh WK; Axtell AE; Kelley JL; Zanotti KM;
Gynecol Oncol; 2009 Nov; 115(2):244-8. PubMed ID: 19712966
[TBL] [Abstract][Full Text] [Related]
26. A review of the pathology and management of uterine papillary serous carcinoma and correlation with outcome.
Faratian D; Stillie A; Busby-Earle RM; Cowie VJ; Monaghan H
Int J Gynecol Cancer; 2006; 16(3):972-8. PubMed ID: 16803471
[TBL] [Abstract][Full Text] [Related]
27. Analysis of clinical and pathological characteristics, treatment methods, survival, and prognosis of uterine papillary serous carcinoma.
Solmaz U; Ekin A; Mat E; Gezer C; Dogan A; Biler A; Peker N; Hasdemir PS; Sanci M
Tumori; 2016 Dec; 102(6):593-599. PubMed ID: 27514313
[TBL] [Abstract][Full Text] [Related]
28. Uterine papillary serous carcinoma: a study on 108 cases with emphasis on the prognostic significance of associated endometrioid carcinoma, absence of invasion, and concomitant ovarian carcinoma.
Carcangiu ML; Chambers JT
Gynecol Oncol; 1992 Dec; 47(3):298-305. PubMed ID: 1473741
[TBL] [Abstract][Full Text] [Related]
29. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
[TBL] [Abstract][Full Text] [Related]
30. Effects of hormone receptor status on patient clinic and survival in HER2 positive breast cancer.
Yılmaz M; Erdiş E; Uçar M; Demir N; Alandağ C; Yücel B
Jpn J Clin Oncol; 2024 May; 54(5):521-529. PubMed ID: 38336481
[TBL] [Abstract][Full Text] [Related]
31. Trastuzumab with carboplatin/paclitaxel for treatment of advanced stage and recurrent uterine papillary serous carcinoma: A cost-effectiveness analysis.
Batman S; Bohn J; Weisenberger MW; Hersh A; Bruegl A; Caughey A; Winter W
Gynecol Oncol; 2021 Jan; 160(1):214-218. PubMed ID: 33393480
[TBL] [Abstract][Full Text] [Related]
32. Moderate HER2 expression as a prognostic factor in hormone receptor positive breast cancer.
Eggemann H; Ignatov T; Burger E; Kantelhardt EJ; Fettke F; Thomssen C; Costa SD; Ignatov A
Endocr Relat Cancer; 2015 Oct; 22(5):725-33. PubMed ID: 26187126
[TBL] [Abstract][Full Text] [Related]
33. Prognostic significance of estrogen, progesterone and HER2 receptors' status conversion following neoadjuvant chemotherapy in patients with locally advanced breast cancer: Results from a tertiary Cancer Center in Saudi Arabia.
Al-Saleh K; Salah T; Arafah M; Husain S; Al-Rikabi A; Abd El-Aziz N
PLoS One; 2021; 16(3):e0247802. PubMed ID: 33667252
[TBL] [Abstract][Full Text] [Related]
34. Quantitative hormone receptor (HR) expression and gene expression analysis in HR+ inflammatory breast cancer (IBC) vs non-IBC.
Iwase T; Harano K; Masuda H; Kida K; Hess KR; Wang Y; Dirix L; Van Laere SJ; Lucci A; Krishnamurthy S; Woodward WA; Layman RM; Bertucci F; Ueno NT
BMC Cancer; 2020 May; 20(1):430. PubMed ID: 32423453
[TBL] [Abstract][Full Text] [Related]
35. Prognostic determinants in patients with stage IIIC and IV uterine papillary serous carcinoma.
Rauh-Hain JA; Growdon WB; Schorge JO; Goodman AK; Boruta DM; McCann C; Horowitz NS; del Carmen MG
Gynecol Oncol; 2010 Nov; 119(2):299-304. PubMed ID: 20691465
[TBL] [Abstract][Full Text] [Related]
36. Overall Survival of Men and Women With Breast Cancer According to Tumor Subtype: A Population-based Study.
Leone J; Zwenger AO; Leone BA; Vallejo CT; Leone JP
Am J Clin Oncol; 2019 Feb; 42(2):215-220. PubMed ID: 30499840
[TBL] [Abstract][Full Text] [Related]
37. Early and Locally Advanced Metaplastic Breast Cancer: Presentation and Survival by Receptor Status in Surveillance, Epidemiology, and End Results (SEER) 2010-2014.
Schroeder MC; Rastogi P; Geyer CE; Miller LD; Thomas A
Oncologist; 2018 Apr; 23(4):481-488. PubMed ID: 29330212
[TBL] [Abstract][Full Text] [Related]
38. Survival advantage associated with multimodal therapy in women with node-positive (stage-IIIC) uterine papillary serous carcinoma: a National Cancer Database study.
Lin JF; Muñiz K; Sukumvanich P; Gehrig P; Beriwal S; Kelley JL; Edwards RP; Olawaiye AB
BJOG; 2016 Oct; 123(11):1846-52. PubMed ID: 26537059
[TBL] [Abstract][Full Text] [Related]
39. Prognostic Impact of Discordance in Hormone Receptor Status Between Primary and Recurrent Sites in Patients With Recurrent Breast Cancer.
Shiino S; Kinoshita T; Yoshida M; Jimbo K; Asaga S; Takayama S; Tsuda H
Clin Breast Cancer; 2016 Aug; 16(4):e133-40. PubMed ID: 27268749
[TBL] [Abstract][Full Text] [Related]
40. Serous carcinoma of the uterus-determination of HER-2/neu status using immunohistochemistry, chromogenic in situ hybridization, and quantitative polymerase chain reaction techniques: its significance and clinical correlation.
Singh P; Smith CL; Cheetham G; Dodd TJ; Davy ML
Int J Gynecol Cancer; 2008; 18(6):1344-51. PubMed ID: 18248390
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]